Your browser doesn't support javascript.
loading
Pulmonary hemodynamics and transplant-free survival in sarcoidosis-associated pulmonary hypertension: Results from an international registry.
Gayen, Shameek K; Baughman, Robert P; Nathan, Steven D; Wells, Athol U; Kouranos, Vasilis; Alhamad, Esam H; Culver, Daniel A; Barney, Joseph; Carmoma, Eva M; Cordova, Francis C; Huitema, Marloes; Scholand, Mary Beth; Wijsenbeek, Marlies; Ganesh, Sivagini; Birring, Surinder S; Price, Laura C; Wort, Stephen J; Shlobin, Oksana A; Gupta, Rohit.
Afiliação
  • Gayen SK; Department of Thoracic Medicine and Surgery Lewis Katz School of Medicine at Temple University Hospital Philadelphia Pennsylvania USA.
  • Baughman RP; Department of Medicine University of Cincinnati Medical Center Cincinnati Ohio USA.
  • Nathan SD; The Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA.
  • Wells AU; Interstitial Lung Disease/Sarcoidosis unit Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London London UK.
  • Kouranos V; Interstitial Lung Disease/Sarcoidosis unit Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London London UK.
  • Alhamad EH; Division of Pulmonary Medicine, College of Medicine King Saud University Riyadh Saudi Arabia.
  • Culver DA; Department of Pulmonary Medicine, and Department of Inflammation and Immunity Cleveland Clinic Cleveland Ohio USA.
  • Barney J; The University of Alabama at Birmingham School of Medicine Birmingham Alabama USA.
  • Carmoma EM; Pulmonary and Critical Care, Mayo Clinic Rochester Minnesota USA.
  • Cordova FC; Department of Thoracic Medicine and Surgery Lewis Katz School of Medicine at Temple University Hospital Philadelphia Pennsylvania USA.
  • Huitema M; Department of Cardiology Sint Antonius Hospital Nieuwegein Netherlands.
  • Scholand MB; University of Utah School of Medicine Salt Lake City Utah USA.
  • Wijsenbeek M; Department of Respiratory Medicine Centre of Excellence for Interstitial Lung Diseases and Sarcoidosis, Erasmus Medical Centre Rotterdam The Netherlands.
  • Ganesh S; Pulmonary, Critical Care and Sleep Medicine Keck School of Medicine of the University of Southern California Los Angeles California USA.
  • Birring SS; Centre for Human & Applied Physiological Sciences School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London London UK.
  • Price LC; National pulmonary hypertension service Royal Brompton Hospital London UK.
  • Wort SJ; Royal Brompton Hospital London UK.
  • Shlobin OA; The Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA.
  • Gupta R; Department of Thoracic Medicine and Surgery Lewis Katz School of Medicine at Temple University Hospital Philadelphia Pennsylvania USA.
Pulm Circ ; 13(4): e12297, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37840561
ABSTRACT
Pulmonary hypertension (PH) is a risk factor for mortality in patients with sarcoidosis. Severe PH in chronic lung disease has previously been defined as mean pulmonary arterial pressure (mPAP) ≥ 35 mmHg or mPAP 25 ≥ mmHg with cardiac index (CI) ≤ 2 L/min/m2. However, there is no clear definition denoting severity of sarcoidosis-associated PH (SAPH). We aimed to determine pulmonary hemodynamic cut-off values where transplant-free survival was worse among patients with SAPH. This was a retrospective cohort analysis of the Registry of SAPH database focusing on pulmonary hemodynamic predictors of transplant-free survival among patients with precapillary SAPH. Cox regression was performed to determine which pulmonary hemodynamic values predicted death or lung transplantation. Kaplan-Meier survival analysis was performed on statistically significant predictors to determine pulmonary hemodynamic cut-off values where transplant-free survival was decreased. Decreased transplant-free survival occurred among SAPH patients with mPAP ≥ 40 mmHg and SAPH patients with pulmonary vascular resistance (PVR) ≥ 5 Woods units (WU). Transplant-free survival was not decreased in patients who fulfilled prior criteria of severe PH in chronic lung disease. We identified new cut-offs with decreased transplant-free survival in the SAPH population. Neither cut-off of mPAP ≥ 40 mmHg nor PVR ≥ 5 WU has previously been shown to be associated with decreased transplant-free survival in SAPH. These values could suggest a new definition of severe SAPH. Our PVR findings are in line with the most recent European Society of Cardiology/European Respiratory Society guideline definition of severe PH in chronic lung disease.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pulm Circ Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pulm Circ Ano de publicação: 2023 Tipo de documento: Article